Sep 22, 2026 · 5 min
Obesity data lifts Viking as lab reimbursement cuts hit
Viking Soars; On Holding Climbs; Quest Diagnostics Drops
The episode shows how clinical evidence, corporate strategy, and government payment policy can move very different stocks at once.
- 1Viking Therapeutics rose after data showed patients maintained weight loss with less frequent obesity-drug dosing.
- 2On gained on a bullish three-year plan, strong sales expectations, and authorization for a $1 billion share buyback.
- 3Quest Diagnostics and LabCorp fell as preliminary Medicare rates pointed to significant cuts in lab-service reimbursements.
Don't miss
Viking Therapeutics rises after data indicate patients maintained weight loss with less frequent dosing.
The brief
Bloomberg’s market roundup focuses on three sharply different catalysts: encouraging obesity-treatment data at Viking Therapeutics, an aggressive growth plan at On, and reimbursement pressure on diagnostic labs.
Viking rose after data suggested patients could maintain weight loss despite less frequent dosing, making the treatment update the episode’s clearest clinical catalyst.
On climbed after outlining a bullish three-year plan, strong sales expectations, and a $1 billion share-buyback authorization—signals of confidence in its growth trajectory.
Quest Diagnostics and LabCorp moved lower when preliminary Medicare payment rates implied significant cuts to lab-service reimbursements, turning policy detail into an immediate market risk.
Together, the moves show how stocks can respond to evidence about a drug, management’s capital-allocation plans, and the reimbursement rules shaping healthcare economics.
What was said on this episode
3 statements · 2 positive · 1 negative
Viking Therapeutics’ results signal optimism for obesity-drug weight-loss maintenance.
“Viking Therapeutics results are really an optimistic sign for that particular process.”
Listen at 1:28
Stifel expects On Holding to gain the most athletic-footwear market share over five years.
“Stifel analysts view On Holding as, quote, the number one market share gainer in athletic footwear over the next 5 years.”
Listen at 2:21
Medicare lab-service reimbursement cuts may exceed expectations and continue through 2028–2029.
“Piper Sandler analysts wrote that the cuts look bigger than expected, and they warned that these cuts could continue into 2028 and 2029.”
Listen at 2:51
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Judy LagrouMentioned
Viking Therapeutics
Bloomberg L.P.Listen to the full episode and explore every guest, topic, and moment on PodLume.